With short interest at 26,337,802 and short average daily volume at 27,541,901, days to cover is 1.0 and the short interest percentage is 0.23% as of October 13. This ratio is calculated by dividing the current share price by the book value per share.
Several equities research analysts recently weighed in on MNKD shares.
Taking a broader look at the analyst consensus, according to 2 analysts Mannkind Corporation (NASDAQ:MNKD)'s price will reach at $7 during 52 weeks. The rating scale runs from 1 to 5 with 5 indicating a Strong Sell, 1 indicating a Strong Buy and 3 indicating a Hold. Finally, HC Wainwright began coverage on MannKind Corporation in a report on Tuesday, October 10th. Three investment analysts have rated the stock with a sell rating, two have assigned a hold rating and one has issued a buy rating to the company's stock. ValuEngine downgraded MannKind Corporation from a "buy" rating to a "hold" rating in a report on Tuesday, August 1st. GOLDMAN SACHS GROUP INC owned 33.38% of MannKind Corporation (MNKD) worth $6.75 million at the end of the most recent reporting period. The shares were bought at an average cost of $6.00 per share, for a total transaction of $999,600.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. They set a "buy" rating on the stock. LMR Partners LLP purchased a new stake in MannKind Corporation during the 2nd quarter worth approximately $352,000.
Harel Insurance Investments & Financial Services Ltd. downsized its ownership by shedding 2,460,000 shares a decrease of 83.4%. During the same period in the previous year, the firm posted $1.30 earnings per share. analysts predict that MannKind Corporation will post -1.13 earnings per share for the current year. KCG Holdings Inc. now owns 147,952 shares of the biopharmaceutical company's stock valued at $219,000 after purchasing an additional 107,752 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in MannKind Corporation by 30.2% during the 3rd quarter. Approximately 40.9% of the shares of the stock are short sold. Company insiders own 1.60% of the company's stock.
The FCF Growth of MannKind Corporation (NasdaqGM:MNKD) is 0.558584.
MannKind Corporation (NasdaqGM:MNKD) presently has a current ratio of 0.31. The ROIC 5 year average of MannKind Corporation (NasdaqGM:MNKD) is -0.925284. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.11). MannKind Corporation had a negative return on equity of 24.93% and a negative net margin of 155.83%.
Mannkind Corporation (NASDAQ:MNKD) has average revenue estimates of $4.43 Million, compared to low analyst estimates of $4.2 Million and high estimates of $4.66 Million for the current quarter. Wells Fargo & Company MN raised its position in shares of MannKind Corporation by 51.5% in the 3rd quarter.
TRADEMARK VIOLATION WARNING: "Short Interest in MannKind Corporation (MNKD) Increases By 11.3%" was reported by TrueBlueTribune and is the sole property of of TrueBlueTribune. If you are reading this report on another publication, it was illegally stolen and republished in violation of US & worldwide copyright legislation.
MannKind Corporation a U.S. based Company, belongs to Healthcare sector and Biotechnology industry. The Firm is focused on the discovery and development of therapeutic products for diseases, such as diabetes. The Business's product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and also to improve glycemic control.